Q32 Bio to Participate in Upcoming September Investor Conferences
Management will discuss clinical programs and investor outreach in three conference presentations, with webcasts and archived replays available after each event.
- Multiple firms, including Palladyne AI, BridgeBio Pharma, and IDEAYA Biosciences, announced this week they will participate in investor conferences throughout September 2026, providing platforms for management to discuss development strategies and corporate pipelines.
- Executives from Editas Medicine and Q32 Bio will host fireside chats to discuss research pipelines covering gene editing and alopecia areata treatments, updating investors on corporate progress and development milestones.
- Scheduled events include the Wells Fargo Healthcare Conference in Boston on Tuesday, September 8, and the Cantor Global Healthcare Conference in New York on Wednesday, September 9, where management teams will conduct presentations and one-on-one meetings.
- Investors can access most sessions via live audio webcasts on company websites, with archived replays remaining available for approximately 30 days following each event.
- Strategic planning extends beyond September, with IDEAYA Biosciences scheduling an R&D investor day in London on November 16 to discuss MTAP/CDKN2A and KRAS development strategies in pancreatic cancer.
20 Articles
20 Articles
Morgan County Citizen
inovio.comINOVIO to Participate in Upcoming Investor Conferences
PLYMOUTH MEETING, Pa., Sept. 1, 2026 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer and infectious diseases, today announced that it will participate in…
ARS Pharmaceuticals to Participate in Upcoming Investor Conferences
SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to treat and prevent severe allergic reactions, today announced that Donn Casale, President and CEO, will…
North Bay Nipissing
Financial PostProMIS Neurosciences to Participate in Upcoming Conferences and Events in September
CAMBRIDGE, Mass, Sept. 01, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced that it will participate in upcoming September 2026 conferences…
BridgeBio to Participate in September Investor Conferences
PALO ALTO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, today announced that members of its management team will participate…
Q32 Bio to Participate in Upcoming September Investor Conferences
WALTHAM, Mass., Sept. 1, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata ("AA") and other autoimmune and inflammatory diseases, today announced that management will participate…
Coverage Details
Bias Distribution
- 63% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
